commercialization agreement
Merck, Daiichi Sankyo Ink Deal to Develop Three Antibody-Drug Conjugates
Patritumab deruxtecan, under development for EGFR-mutated NSCLC, is one of the drugs in the deal, which has a total financial consideration of $22 billion.
Roche to Terminate Gavreto Deal With Blueprint Medicines
Blueprint will regain global commercialization rights for the RET inhibitor following Roche's decision to end the collaboration for strategic reasons.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.
Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
Pierre Fabre bought the EU commercialization rights to tabelecleucel, which Atara expects European regulators to approve for EBV-positive cancer this year.
Legend Biotech Nets $50M Milestone Payment From Janssen for Carvykti
The payment was triggered by the commercialization of the recently FDA-approved CAR T-cell therapy for multiple myeloma.